PTC Therapeutics (PTCT) PT Lowered to $53 at JPMorgan, 'Late Stage Assets Remain Significantly Underappreciated'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
PTC Therapeutics (PTCT) PT Lowered to $45 at Truist Securities; 'PTC isn't dead'
September 18, 2023 6:14 AM EDTTruist Securities analyst Robyn Karnauskas lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $45.00 (from $60.00) while maintaining a Buy rating.
THE analyst commented, "In addition to the negative CHMP decision, we believe concerns about cash position and mgmt's ability to... More
Raymond James Downgrades PTC Therapeutics (PTCT) to Underperform, 'expect the drug to be officially pulled from the EU market by January 2024'
September 15, 2023 9:06 AM EDT(Updated - September 15, 2023 9:18 AM EDT)
Raymond James analyst Danielle Brill downgraded PTC Therapeutics (NASDAQ: PTCT) from Outperform to Underperform.
The analyst comments "We are downgrading PTCT to Underperform following this mornings new release that the CHMP issued a negative opinion for the... More
PTC Therapeutics' (PTCT) Translarna Receives Negative CHMP Opinion
September 15, 2023 6:00 AM EDTPTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has given a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The negative opinion also applies to the renewal of the existing conditional authorization. PTC plans to submit a request for re-examination per EMA guidelines. Translarna will remain on the market and available to... More
